March 9, 2020
The Japan arm of Gilead Sciences said on March 6 that research on large-scale clinical data has shown the efficacy and safety of a switch to its chronic hepatitis B treatment Vemlidy (tenofovir alafenamide fumarate) from existing drugs. Data were...read more